TEMCER
A modular fusion reactor and high-intensity neutron-source platform. TEMCER uses a magnetic-mirror field configuration and combines the academic routes of WHAM and CMFX. Its development objective is a controllable magnetic-confinement topology that supports operation without requiring full ignition.
The commercial path starts with medical-isotope processing and neutron irradiation services. The same core platform then progresses toward fusion power. Modular construction supports standardized manufacturing and capacity growth through independently operated or coordinated reactor arrays.
Performance & Applications
The first commercial neutron-service target is 10¹⁶ neutrons per second at 14.1 MeV, with 10¹⁷ n/s as a development expansion target. Commercial irradiation and fusion research can use the same equipment in different operating modes.
Applications include Lu-177 NCA / CA, Mo-99, Ac-225 and other irradiation services. Specialist partners perform downstream radiochemical purification and nuclear medicine manufacturing. Later development targets fusion electricity generation and tritium self-sufficiency, with potential surplus production.
These are development targets to be established through engineering validation and measured performance.
Further Technical Discussion
Detailed architecture, engineering structures and implementation parameters can be discussed after signing a non-disclosure agreement (NDA).
How TEMCER Earns Revenue
The initial business sells neutron irradiation and medical-isotope processing services to isotope suppliers and radiopharmaceutical manufacturers. Downstream specialists handle purification and drug manufacturing.
Later development adds electricity sales, potential surplus-tritium sales and licensing of reactor technology. Cross-industry intellectual property can provide an additional licensing pathway.
Market Scale
Medical-isotope applications serve radiopharmaceutical manufacturers, isotope suppliers and Tc-99m generator providers. Potential customer examples include Novartis, Eli Lilly / POINT Biopharma, Lantheus, Telix, Curium and ITM.
The electricity-market scenario in the current pitch addresses a US baseload segment of 155.05 TWh per year, representing approximately 10% of the modeled base market. At the pitch’s electricity-price assumptions, this target segment has an annual electricity value of approximately USD 13.2–20.74 billion.
Planned Market Share
The long-term power-market scenario targets approximately 10% of US baseload electricity, equivalent to about 230 reactor units under the pitch’s deployment assumptions.
The initial market entry focuses on repeatable isotope irradiation services. Commercial availability and modular array deployment support expansion into the later power-market target.
© 2026 BriLo Energy Inc. All rights reserved.